SCFAs can improve the efficacy of ICI therapy by directly promoting the cytotoxic effects of CD8 T cells, regulating tumour signalling pathways, and reducing the expression of inflammatory factors [9, 161, 162]. The gene discussed is CD8A; the disease is neoplasm.